Augmented reality can show local residents future building plans in real time — and Tampa Bay wants in
Sarah Vitale, the director of civic technology at the TBRPC, which provides local governments with technology to aid in climate resilience planning, including flooding and hurricane preparedness, often uses 2D images and renders to showcase new infrastructure, such as stormwater drainage systems. However, these tools failed to show the scale of the projects.
Last year, Vitale partnered with InCitu, a New York-based augmented reality startup, to give communities a clearer picture of future infrastructure developments. "What better way to do that than to really let them experience it in real time in the physical space?" Vitale said.
InCitu's AR platform is designed to help government agencies, real estate developers, urban planners, and architects show colleagues or community members what proposed buildings and infrastructure projects will look like once completed.
"I wanted to communicate this type of information so that a non-professional can experience it as they walk down the street," Dana Chermesh-Reshef, the CEO of InCitu, told Business Insider. InCitu's technology has also launched in seven other US cities, including Washington, DC, and New York.
A new view on infrastructure projects
Chermesh-Reshef founded InCitu in 2020 after realizing the usual software tools used to present infrastructure projects, such as PowerPoint presentations and 2D renders, struggled to show a project's full scale and scope from various angles.
It can also be difficult to imagine a project in an environment like a conference room, entirely removed from where it will exist.
InCitu's smartphone-based platform tackles this by turning 3D models into AR visuals, helping people see a project as it would appear in real life. Instead of using an AR headset, users can scan a QR code with a smartphone camera at a construction site — often a building, bridge, roadway, or sidewalk — to view the life-sized AR visualization.
"You don't have to download any app. You walk down the street, there's a QR code on the ground or on the construction site," Chermesh-Reshef said.
Users can use their smartphones to walk around a project and view it from any angle they can access. InCitu also supports off-site viewing, so users can view a 3D model of the project without visiting its geographical location.
InCitu uses geospatial data, which draws on satellite and street view imagery, to decide where an imported 3D model should appear for on-site viewing. Geospatial data is also used to keep the 3D model in the right location as a user moves around it in the real world.
Using AR to visualize a climate-resilient future
Vitale encountered InCitu on LinkedIn in January 2024 while preparing for TBRPC's annual regional resiliency summit. This two-day event brings together roughly 300 elected officials, subject experts, and residents to find solutions for the region's climate risks. Vitale wanted a way to give attendees a scaled, realistic visualization of building changes and infrastructure that can manage flood risks.
Vitale used InCitu to show three AR models of new projects during on-site visits near the event: a house elevated on stilts to demonstrate flood-resistant construction, a bioswale showing natural stormwater management, and a living shoreline that uses natural materials to combat eroding beaches.
Vitale said that her organization's use of InCitu is still in the "marketing phase" and that its role at the resiliency summit was in part to let attendees and prospective clients know her team can provide AR technology for infrastructure planning. She said the reception so far has been positive.
"It's not a big, dense document. It's something interesting that people can engage with and start experiencing a planning process in a new way," Vitale said. She added that AR displays can reduce the "engagement fatigue" that can accompany lengthy meetings and complex 2D visualizations.
The technology's effectiveness convinced TBRPC to use InCitu for AR demonstrations at its 2025 summit in May. The organization also plans to use InCitu to educate students at local high schools about bioswales and other infrastructure solutions to flooding.
"We can take them to a site that's full of concrete and show them other ways to naturalize the surface, to handle some of the water, when it's pouring rain," Vitale said. She hopes the technology will help students understand alternatives to less permeable "gray" infrastructure, like concrete.
Vital said she expects the use of AR tools like InCitu to become standard practice in urban planning as newer, younger graduates with better knowledge of 3D modeling, AR, and other new technologies enter the field. So far, InCitu has made over 5,000 future developments available in AR, and over 250,000 residents have viewed future projects near their communities using the company's AR platform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
43 minutes ago
- USA Today
WNBA-to-Boston celebrations premature? League pushes back on CT Sun move after Pagliuca deal
Fans celebrating the arrival of the WNBA to the City of Boston might want to temper their expectations in the short term. Recent reporting from the Boston Globe's Gary Washburn relates that the WNBA itself is throwing cold water on ta potential move of the recently-purchased Connecticut Sun to a new location. Former Boston Celtics minority owner and Bain Capital executive Steve Pagliuca recently purchased the team for a record $325 million, with another $100 million earmarked to build a dedicated practice facility for the team in Boston. But per Washburn, after news of the sale broke this week, the league sent the reporter a release pushing back on a potential move out of the Nutmeg state. "Relocation decisions are made by the WNBA Board of Governors and not by individual teams," related the WNBA to Washburn, also noting that "no groups from Boston applied for a team." This could put a bit of a damper on things, given Pagliuca would be one of the first names for an expansion team in the area, yet the former Celtics owner now finds himself the new owner (pending league approval) of a team the WNBA appears determined to keep in Connecticut. "Nine additional cities also applied for WNBA teams and remain under active consideration. Those other cities remain under consideration based on the extensive work they did as part of the expansion process and currently have priority over Boston," added the league. This course of action may have actually put the city behind the proverbial eight ball, as the WNBA may be looking to avoid following in the footsteps of the NBA with the highly unpopular move of the Seattle SuperSonics to Oklahoma City in the aughts. Interestingly, the release tendered to Washburn also notes that a "prospective Celtics owner has also reached out to the league office and asked that Boston receive strong consideration for a WNBA franchise at the appropriate time." Does this mean the ownership group helmed by Bill Chisholm currently in the process of securing final NBA approval to buy the Boston-based NBA ball club is also the leading group to secure a WNBA team in the same city? At present, details on all of the above are murky, but will likely continue to develop in the coming weeks. Listen to "Havlicek Stole the Pod" on: Spotify: iTunes: YouTube:
Washington Post
44 minutes ago
- Washington Post
OPEC+ countries to boost oil production by 547,000 barrels per day
NEW YORK — A group of countries that are part of the OPEC+ alliance of oil-exporting countries has agreed to boost oil production, a move some believe could lower oil and gasoline prices, citing a steady global economic outlook and low oil inventories. The group met virtually on Sunday and announced that eight of its member countries would increase oil production by 547,000 barrels per day in September.
Forbes
an hour ago
- Forbes
UnitedHealth Stock Is Cracking Despite Strong Earnings—Here's What Wall Street Sees
UnitedHealth just reported billions in quarterly profit. Earnings were strong. The company sounded stable. And yet, Wall Street is dumping the stock. Shares are trading near multi-year lows, underperforming peers, and reacting poorly to each quarterly release. The market doesn't move like this for nothing—so what's really going on? Markets often sniff out risks long before they're made official. The headlines are piling up: government investigations, operational failures, and leadership questions, but the price has already started to discount something deeper. Investors are trained to react to numbers. But when structure breaks, the numbers are often the last to go. This isn't about a soft quarter. The model itself is cracking, and the market sees it. The way UnitedHealth generates earnings, the incentives behind its vertical integration, and the regulatory heat all point to fragility that isn't captured in consensus spreadsheets. The market is whispering what many investors don't want to admit: that something is changing here. And once trust fades, the re-rating isn't temporary. It's structural. UnitedHealth Stock: Big, Profitable, Misunderstood UnitedHealth trades with a market value of about $226 billion, against $400 billion in revenue for 2024, with 2025 revenue expected to reach mid‑$445 billion to $448 billion. Size doesn't really equal a safe company; it often hides the fragility beneath. Most investors can't describe how the business works. They see adjusted EPS. They don't question the mechanics. They assume that anything producing this much cash must be built to last. But what looks durable can rot from the inside. The core of UnitedHealth's engine is vertical integration. Optum decides on care, delivers it, and pays itself. One hand washes the other, all under the same roof. It's efficient when unexamined. But regulators are finally paying attention. When the payer, provider, and data all sit in one unit, it becomes harder to separate health outcomes from billing outcomes. Investors often mistake size for insulation. But complexity cuts both ways. When that model starts to wobble, through government probes, whistleblower claims, or unexplained earnings distortions, it doesn't usually collapse overnight. It slowly leaks. This is what we are witnessing. The price action is the tell. This isn't about sentiment anymore. It's about what the market now knows; the market no longer trusts what it thought it understood. You can see it is undone. Slowly at this point. But it's picking up. UnitedHealth Is In The Crosshairs Of The Regulators The Department of Justice now runs both criminal and civil investigations into UnitedHealth's Medicare Advantage billing, officially confirmed on July 24, 2025. Washington is targeting diagnostic coding and risk adjustment practices tied to higher payouts. A process investigators say may have involved pressure, bonuses, and algorithmic recommendations to staff for certain lucrative diagnoses. At the center is Optum, UnitedHealth's massive care delivery and analytics arm, which assigns diagnoses, delivers services, and influences payer reimbursement. That vertical structure underpinned margin expansion until it became a regulatory vulnerability. Congress and CMS are now eyeing those same incentives for bundled services that may prioritize profit over care. And according to multiple reports, lawmakers are drafting reforms to Medicare Advantage to clamp down on what they see as systemic abuse. This is more than a compliance issue. If enforcement leads to fines or limits on Optum's ability to steer claims, UnitedHealth loses both margin and narrative. The company disclosed a potential settlement cost of $1.6 billion tied specifically to these investigations. For investors, this isn't a question of past performance but future structure. If Washington forces a redesign in how payer, provider, and auditor relationships operate within Optum, valuation multiples change. You won't see regulatory risk on a spreadsheet. It's not in the line items. But it's in every fund manager's head. And the market is already pricing that doubt. Earnings Vs. Trust UnitedHealth keeps beating the numbers. But the market's not cheering anymore, and that should make investors stop to think. Second‑quarter 2025 adjusted EPS came in at $4.08, while GAAP net earnings per share were about $3.74, reflecting a 9‑10% spread. This isn't a one-off. The company has leaned on adjustments for several quarters, removing charges from cyberattacks, restructuring, litigation, and 'normalizing' expense items. Each quarter it gets harder to square the adjusted reality with the actual income statement. Investors have tolerated this because the stock used to respond. Now, even beats fall flat. The post-earnings reaction in July was strong, with headline numbers, and yet shares sank over 4%. It's not the earnings they're questioning. It's the whole premise. When the market no longer trusts the adjustment logic, the premium unwinds. At some point, 'adjusted' starts sounding like wishful thinking. That's a dangerous pivot for a stock that trades on perceived consistency. The issue here is credibility. And when credibility gets questioned in a complex, vertically integrated healthcare giant with active DOJ probes and massive opacity in its internal operations, the path forward narrows quickly. UnitedHealth's numbers still impress. But the market is no longer listening to the numbers alone. It's watching what they're trying to cover. Optum: The Black Box That Powered Growth At UnitedHealth For years, Optum was UnitedHealth's crown jewel. It gave the company vertical integration that most healthcare giants could only dream of. Run the insurer. Own the doctor's office. Control the pharmacy benefit manager. Route the claims. Capture every step of the dollar. Investors praised it as genius. Until now. Optum was built for margin expansion. By combining payer and provider, UnitedHealth collapsed the value chain into itself. But that same structure is now drawing fire. Regulators are asking whether a company can truly manage care outcomes and approve and profit from the services being recommended. This questions their entire integration strategy. What used to be pitched as 'scale and efficiency' now looks like opacity. Good luck getting through an Optum report without needing aspirin halfway. It's all intentional. In a market that once rewarded complexity, investors are shifting toward simplicity and transparency. Optum is the opposite. Here's the rub: the more essential Optum is to UnitedHealth's story, the more exposed the company becomes to scrutiny. Break the chain or just shake investor faith in it and the premium vanishes. Optum was once the crown jewel. Now it's the bullseye. The Cyberattack Was A Wake-Up Call At UnitedHealth When Change Healthcare, an Optum subsidiary, was hit by a massive ransomware attack earlier this year, most investors treated it as a one-off disruption. It wasn't. It was a systemic failure that revealed how fragile UnitedHealth's infrastructure had become and how slow its leadership was to respond. The breach paralyzed billing and claims systems for weeks across the U.S. healthcare network. Providers couldn't get paid. Pharmacies stalled. Patients were caught in the middle. For a company that sells itself on reliability and integration, the collapse of a core system fully exposed them to operational risk. But the real damage was reputational. CEO Andrew Witty's delayed response and lack of transparency during the fallout shook investor confidence. For a business model that depends on centralized control, a failure of this scale felt like the opposite of control. The market didn't punish the stock immediately, but the tone shifted. Since the hack, UnitedHealth stock has lagged peers, failed to respond to buybacks, and sold off post-earnings despite beats, indicating trust erosion. In healthcare, operational execution is the product. And the cyberattack told the market what the earnings couldn't: UnitedHealth may be bigger than ever, but its foundation isn't as solid as the numbers suggest. Defensive Stocks Are No Longer Safe Havens Investors once treated UnitedHealth like a bond proxy. It was dependable, defensive, and cash-rich, perfect in a zero-rate world, but the world has moved on. And the assumptions that supported its premium are unraveling with it. But investors have moved on. Higher rates change everything. Safety no longer commands a valuation premium. If anything, it draws sharper scrutiny. Now, capital seeks efficiency and flexibility. It rotates out of perceived stability the moment cracks appear. That's exactly what's happening with UnitedHealth. It's mainly about multiples. Stocks like UnitedHealth were priced on the assumption that growth would stay steady, margins wouldn't come under pressure, and regulators would remain passive. That's no longer the case. Every part of the thesis, from Medicare Advantage economics to Optum's integration, is under review. And the old multiple doesn't hold under new conditions. At 9 to 10 times forward earnings, UnitedHealth stock is still priced for control. But what happens if growth slows, scrutiny increases, and earnings quality erodes? That multiple doesn't hold when earnings wobble and faith erodes. And that's what we're starting to see. The idea that defensive means safe no longer applies. In a world where capital costs more and scrutiny cuts deeper, structural risk matters more than past predictability. And UnitedHealth is showing investors what happens when they confuse size for safety. Market Behavior Is Telling The market is speaking louder than the press release. UnitedHealth's earnings keep beating expectations, yet the stock keeps bleeding. After the Q2 2025 print, shares opened higher and then reversed, again indicating doubt from the market. Buybacks, once the reliable support mechanism, are falling flat. As of the April 2025 10‑Q, the board authorized repurchasing 27 million shares, not a dollar amount. Share count & price suggest a rough upper bound of ~$13 billion (assuming ~$500/share), but no official dollar figure exists. The tape hasn't cared. Investors aren't paying for stability anymore. They're questioning the model, and the price is reflecting it. This keeps happening. Strong numbers, weak tape. That's no coincidence. The market is reacting to what those earnings might not be showing. When price action diverges consistently from headline strength, something underneath is shifting. You don't need management to confirm what the price already knows. Scenarios Investors Must Weigh Every investor in UnitedHealth needs to face a simple question: what exactly is being priced in? The stock is still valued like nothing structurally will change. That's the best-case scenario: a regulatory slap on the wrist, no breakup, and margins protected. But cracks like these don't usually stop there. The base case is more uncomfortable. It assumes the DOJ and CMS probes gain traction, triggering forced disclosures, tighter reporting standards, and some form of operational reform. That alone could compress margins across Optum, weaken pricing power, and delay capital returns. It would also likely lower the multiple as the market stops assuming permanence in a business model that's now up for review. The worst case? A permanent re-rating. If the government cracks down on how care is authorized and reimbursed, if whistleblower cases uncover deeper abuses, or if investors lose trust in Optum's structure entirely, then UnitedHealth becomes less of a cash machine and more of a litigation risk. That would mean sustained outflows, ESG scrutiny, and index pressure. Right now, the stock trades like the best-case scenario is a given. That's a mistake. Risk is what you don't see coming, and the market has a habit of mispricing structural changes until they happen. UnitedHealth Stock Is Breaking For A Reason UnitedHealth has long benefited from scale, opacity, and the assumption that healthcare complexity equals safety. That illusion is fading. The stock is breaking not because of a single quarter or a bad headline, but because the structure that powered its dominance is now under the microscope. When investors start asking the right questions, eventually price always does. That's what's happening here. The DOJ, CMS, and media aren't just circling; they're probing a business model that was built on internal leverage and integration. When that's challenged, the numbers don't matter as much as the narrative. And UnitedHealth is losing control of its narrative. This isn't a bad value call. It's something deeper—the kind of unraveling that rewrites the whole thesis. Markets don't punish giants like this without reason. When scrutiny hits complexity, it always takes time, but it always resets expectations. UnitedHealth isn't priced for scrutiny. And when the foundation cracks, the market doesn't wait for permission to react; it already has.
